8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

8.2.1. Cytotoxic medicines

Methotrexate

**Indication**
Acute myeloid leukaemia with recurrent genetic abnormalities

**INN**
Methotrexate

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt) ; 50 mg per 2 mL ; 1000 mg per 10 mL concentrated injection
- Oral > Solid: 2.5 mg (as sodium salt)

**EML status history**
- First added in 2015 (TRS 994)
- Changed in 2019 (TRS 1021)
- Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Tags**
- Cancer

**Wikipedia**
Methotrexate

**DrugBank**
Methotrexate

**Summary of evidence and Expert Committee recommendations**
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of additional dose forms of methotrexate (Injection: 50 mg/2 mL and Concentrated injection: 1000 mg/10 mL) to the EML and EMLc.